News
CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
First paragraph, second sentence of release should read: Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss Clovis’ results and business outlook in
GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719006077/en/
Figure 1. Evolution of BCVA In LUMEVOQ®-treated
Humana Foundation Announces Scholarship Awards
The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, announced 75 winners of college scholarships awarded through The Humana Foundation Scholarship
DGAP-News: Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
DGAP-News: Evotec completes acquisition of Rigenerand
DGAP-News: Gerresheimer AG: Gerresheimer signs new credit facility in the amount of 150 million Euro
Acadia Healthcare Names R. David Kelly to Board of Directors
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that R. David Kelly has been appointed to serve as an independent director on the Company’s Board of Directors.
This press release
DGAP-News: Evotec SE reports results of Annual General Meeting 2022
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: Evotec enters a drug discovery collaboration with Janssen
DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Humana Launches CenterWell Pharmacy and CenterWell Specialty Pharmacy
Humana Inc. (NYSE: HUM), a leading health and well-being company, has announced that Humana Pharmacy and Humana Specialty Pharmacy are now CenterWell Pharmacy and CenterWell Specialty Pharmacy
Gerresheimer AG: Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease
Waters stellt hochauflösende Massenspektrometrie-Produkte und -Software zur Beschleunigung der Wirkstoffentwicklung vor
ASMS 2022 – Die Waters Corporation (NYSE:WAT) hat heute auf der Jahreskonferenz der American Society for Mass Spectrometry 2022 (ASMS) neue Instrumente, Softwarelösungen und Produktverbesserungen
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated
STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer® Lens (ICL)
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than two million
Waters Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development
ASMS 2022 – Waters Corporation (NYSE:WAT) today unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry
Humana Adds 14 States in Phase 2 of CenterWell Home Health Launch
Humana Inc. (NYSE: HUM) has announced the addition of 14 states to the ongoing initiative to rebrand the home health division of Kindred at Home (KAH) as CenterWell Home Health. The announcement of
Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), announced today that people with type 1 and type 2 diabetes age two and over on multiple daily
Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), announced today that people with type 1 and type 2 diabetes age two and over on multiple daily
DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand